All Tirzepatide certificates

Tirzepatide 10 mg Certificate of Analysis Batch APL-TIRZ10-2608-01

Tirzepatide 10 mg from batch APL-TIRZ10-2608-01 was analysed on 31 August 2026 and measured 99.05% purity by HPLC / Mass Spectrometry, passing all 5 release tests.

Purity
99.05%
Result
All 5 tests passed
Tested
31 August 2026
Method
HPLC / Mass Spectrometry
Net content
10.12 mg

Independent verification

Tirzepatide 10 mg is independently verified by Ozcanium Analytics, an independent Australian laboratory, at 98.77% purity by UPLC-MS/MS, analysed 7 September 2026 on lot APL-TIRZ10-2609-01, net content 10.97 mg, verification code OZ-HPLCMS-TP99; bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL, analysed 8 September 2026, verification code OZ-ENDOTX-TEP1.

Issued by Ozcanium Analytics. Covers every vial size of this compound; each report opens as the laboratory issued it.

Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.

The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 1 of 2

Certificate of Analysis Tirzepatide 10 mg Batch APL-TIRZ10-2608-01
Compound
Tirzepatide
Lot Number
APL-TIRZ10-2608-01
Analysis Date
31 August 2026
Method
HPLC / Mass Spectrometry
Purity
99.05%
Net Content
10.12 mg
Tirzepatide vial
CAS Number
2023788-19-2
Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Form
Lyophilised Powder
Manufactured
August 2026
Issued
1 September 2026
Document ID
APL-COA-TIRZ10-2608-01
Verification Code
Batch traceable
Sequence39 amino acid dual GIP/GLP-1 agonist on a GIP backbone, C-terminally amidated; Aib at positions 2 and 13, Lys20 conjugated via gamma-Glu-AEEA-AEEA to a C20 fatty diacid

High Performance Liquid Chromatography (HPLC-UV) Chromatogram

mAUPDA 214 nm025050075010003.544.555.566.577.58 min 4.2404.4904.710Tirzepatide5.1306.950

Main peak integrated at 99.05% of total area; no single impurity peak exceeds 0.38%.

Peak List

Peaks detected: 5
#Time (min)Area% AreaIdentification
14.24015,8400.220—
24.49027,3600.380—
34.7107,131,60099.050Tirzepatide
45.13017,2800.240—
56.9507,9200.110—

Analytical Results

TestSpecificationResultStatus
AppearanceWhite/Off-White Lyophilised PowderConformsPASS
Identity (MS)ConfirmedConfirmedPASS
Purity (HPLC)≥98.0%99.05%PASS
Peptide Content95–105%98.8%PASS
Endotoxins<0.5 EU/mg<0.20 EU/mgPASS

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 2 of 2

Tirzepatide 10 mg

CAS Number: 2023788-19-2

Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis

Identity confirmation with SIM

Analysis date: 31 August 2026
Monitored (m/z)Detected (m/z)Relative Intensity
964963.731.35
12041204.411.9
16051605.531.05

Detection assignment: Tirzepatide

Collected Mass Spectrum

Intensity ×107

00.511.5260080010001200140016001800 m/z 96412041606

Verification Protocol

  • Identity confirmed by mass spectrometry against the expected ion channels.
  • Purity measured by HPLC as peak area against all integrated impurity peaks.
  • Batch traceability: this document reports the lot number printed on the vial.
  • Analysis performed in-house by Australian Peptide Labs.

Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.

View Tirzepatide in the catalogueHow to read this certificate